A379 treatment regimens. The impact of patient profile (defined in terms of historical and pre-ITI titre levels, age at ITI, age at diagnosis of inhibitors) and FVIII dosage regimen on success rates and duration of ITI were estimated via simulation and competing risk survival models using data from 113 patients enrolled in two large ITI registries. RESULTS: A typical patient initiating ITI with a FVIII dosage of 50-199 IU/Kg/day has an estimated 70% success rate. The median time to ITI completion was estimated at 15 months. The FVIII-related costs (discounted at 3%) were $1,101,250. The main cost driver was the FVIII dosage. For instance, ITI costs ranged from $227,650 for a 58% success probability with a low-dose ( 50 IU/kg/day) FVIII dosage regimen to $3,281,000 for a 78% success probability on a high-dose ( 200 IU/kg/day) regimen. Inhibitor titre levels at ITI initiation and historical peak inhibitor levels also impact ITI costs, but to a lesser degree than ITI dosage. For instance, patients with historical peak titres 50% higher than average incur 10% to 18% higher ITI costs, depending on dosage. However, titre levels were predicted to impact success rates to a degree comparable to that of dosage. CONCLUSIONS: ITI costs and success rates are driven in part by the FVIII dosage and the patient's risk profile. Ensuring that patients initiate ITI with the best possible profile and on the most appropriate regimen has important implications in terms of costs and clinical outcomes.
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Novo Nordisk Pharma S.A.S., Zurich Oerlikon, Switzerland, 2 Novo Nordisk Pharma S.A.S., Casablanca, Morocco, 3 IMS Health, Barcelona, Spain OBJECTIVES: To estimate the cost of treating patients with haemophilia and inhibitors in Morocco. METHODS: A systematic literature research was performed to identify data on the epidemiology and cost of haemophilia. In order to collect information about the characteristics of patients, treatment options available and prescribed, and the use of health care resources, a structured questionnaire was developed and sent to Moroccan key opinion leaders in haemophilia. Data were collected from the completed questionnaires and validated in a consensus meeting. A decision analytic model was developed to estimate the average direct medical costs per patient per year from the Moroccan NHS perspective. A sensitivity analysis was conducted, also considering values from the literature about other countries. RESULTS: Information about the characteristics and the management of Moroccan patients with haemophilia and inhibitors is scarce in the literature. Parameters from international literature and also values reported by the experts show a wide range in key variables, like patients' weight, number of bleeding episodes, distribution of mild/moderate or severe patients and number of severe episodes. Estimated annual total costs were on average 1,754,635MAD (a159,145) per patient. After completing the sensitivity analysis, it was estimated that the average cost per patient could vary from 438,658 DHM (a39,786) to 2,485,734 (a225,456) . CONCLUSIONS: It is challenging to complete a cost study in a country where there are limited sources of local medical information, and especially in a low prevalence disease such as haemophilia. As experts see limited number of patients with inhibitors, there is a high level of uncertainty about the patients' characteristics, their management and therefore the key variables that drive costs. Despite the wide range in the cost estimates, this type of cost studies contribute to the better understanding of the disease and provide useful information for decisions related to the allocation of resources.
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COST OF OBESITY TREATMENT IN POLAND
Macioch T 1 , Perkowski P 1 , Jarosz A 2 , Hermanowski T 1 1 Medical University of Warsaw, Warsaw, Poland, 2 National Food and Nutrition Institute, Warsaw, Poland OBJECTIVES: More than 12% of adult population in Poland (4 million people) are obese (BMI 30), with approximately 400 thousand being extremely obese (BMI 40). In Western Europe up to 4% of total expenditures on health are spent on managing obesity and obesity dependent chronic diseases including diabetes, cardiovascular diseases and cancer. The aim of this study was to estimate direct cost of managing obesity in Poland. METHODS: Direct costs of obesity treatment were measured from both public payer's (National Health Fund, NHF) and patients perspective. Data regarding standard obesity care were prospectively collected in a population of 72 obese patients, treated in National Food and Nutrition Institute in Warsaw. Data regarding bariatric surgery were provided by experts. Cost data were calculated based either on NHF data (public payer perspective) or current market prices (patients perspective). Values are presented in Euro (exchange rate: 1 Euro 4,50 PLN). RESULTS:
We estimate annual cost of obesity care at 325 Euro per patient. with more than 63% representing direct medical costs. Based on number and sort of bariatric surgery performed in 2008 in Poland we estimate total cost of surgical treatment for more than a2.2 mln (all covered by public payer). Based on NHF data, we estimate less than 30 thousand obese patients being covered with specialized medical care. Given that, total annual cost of obesity treatment in Poland would be as low as a12 mln, representing about 0,07% of total expenditures on health in 2008. Direct medical cost covered by public payer were estimated at 4 mln Euro representing less than 0,05% of NHF expenditures in 2008. Approximately two-thirds of obesity therapy costs are covered by patients. CONCLUSIONS: Regarding annual cost of managing obesity dependent diseases estimated at a550 mln, obesity therapy expenditures seems to be rather low in Poland. To carry on a costing of the processes involved in first line of Non-Hodgkin's Lymphoma (NHL) at private hospital en Mexico. METHODS: In order to define resources and procedures to set the direct medical costs of treatment of NHL included treatment, following and medical support; a retrospective review of medical histories of a private hospital en Mexico. The revision of the clinical files include patients treated between the fourth quarterly of 2000 and the fourth quarterly of 2006. A total of 106 patients were selected but only in 44 cases treatment's response were reported and therefore considered for costing the disease. RESULTS: A total of 44 patients full fill the inclusion criteria, with a mean age of 55 years (12 to 85); Male 57% (25) and Female 43% (19); and a Karnofsky of 100% 8 cases, of 90% 6 cases, of 80% 7 cases, 40% 1 case and Unknown 22 cases; the initial symptomatology (numbers of cases) were Fever: 20; Diaphoreses: 13; weight lost 10% body weight in the last 3 months: 25; The Treatment received as a first line treatment: Chemotherapy 41 and chemotherapy plus radiotherapy 3 with a mean of 2.7 (1-12) cycles. The response to the first line of treatment (numbers of cases) was: Partial response: 3, Progression: 19, Death: 15 and Unknown: 7. Costs of Chemotherapy drugs and its application US$4,057.07 ($2,337.04-$5,777.09), hematological support US$990.97 ($333.83-$1,648.12), studies and laboratories US$1,383.38 ($712.23-$2,054.52), adverse events US$5,125.59 ($1,980.12-$8,271.06), radiotherapy US$84.74 ($0.00-$183.27). Total cost US$11, 641.76 ($6, 744.21) . CONCLUSIONS: The Costs related to Chemotherapy drugs, its application and the presence of adverse events do the chemotherapy represents almost 79% of the total cost of first line treatment of Non-Hodgkin's Lymphoma, which diminishes the importance of having alternatives that offer a security profile in order to achieve a more efficient use of the available resources.
PSY23
COST OF FIRST LINE TREATMENT OF NON-HODGKIN'S LYMPHOMA AT PRIVATE HOSPITAL EN MEXICO
PSY24 A COST CONSEQUENCE EVALUATION OF TWO MODELS OF CARE OF OUTPATIENTS WITH CHRONIC NEUROPATHIC PAIN IN NEUROLOGY SETTINGS IN SPAIN: GENERAL CLINICS VERSUS SPECIALIZED PAIN CLINICS
Matías-Guiu J 1 , Guerrero M 2 , López-Trigo J 3 , Montero J 4 , Ortega A 5 , Rejas J 6 1 Hospital Clinico Universitario San Carlos, Madrid, Spain, 2 Universidad Católica de Murcia, Murcia, Spain, 3 Hospital General Universitario de Valencia, Valencia, Spain, 4 Hospital Universitario de Bellvitge, Barcelona, Spain, 5 Hospital Virgen de las Nieves, Granada, Spain, 6 Pfizer Spain, Madrid, Spain OBJECTIVES: To assess the cost-consequences of chronic Neuropathic Pain (NeP) outpatients care comparing management in General Clinics (GC) versus Specialized Pain Clinics (SPC) in Neurology settings in Spain. METHODS: A 6-month retrospective observational non interventional study was designed. Adults, both genders patients with chronic NeP were included in the analysis. Patients were allocated to two type of health care model according to usual administrative procedures in each participant centre without investigator participation, consecutively and independently of the diagnosis and clinical status of patients. Sociodemographics and clinical characteristics of subjects along with pain-related health care and non health care resources utilization were recorded. Work-days missed as a consequence of pain were also collected. Costs were calculated in Euros year 2008 from the societal perspective, while severity and interference of pain (BPI scale, range 0-10) were used for effectiveness. Patient's satisfaction with health care was also assessed. RESULTS: A total of 234 patients (56.8% women, 59.3 14.7 years) were included (53.0% in SPCs). Yearly indirect cost was a1299 2804 in SPC compared to a1483 3452 in GC (p 0.660), while annual direct costs were, respectively, a2911 3335 and a3563 4,797 (p 0.239), with total costs of a4210 4654 and a5060 6250, respectively (p 0,249). Mean pain severity at the time of evaluation was 3.8 2.3 in subjects at SPC versus 5.2 2.0 in GC (p 0.0001), while the average interference of pain on daily activities were, respectively, 3.3 2.0 and 4.7 2.5 (p 0.0001). Patients managed at SPC were statistically more satisfied in all domains of health care satisfaction assessment. CONCLUSIONS: . In Neurology settings in Spain, the outpatient clinical management of chronic NeP in Specialized Pain Clinics was a dominant alternative compared with General Clinics health care, since it was shown better patients health care outcomes and satisfaction while maintaining a similar level of costs to the Society.
PSY25 RENAL ANEMIA (RA) TREATMENT IN MEXICAN PUBLIC HEALTH CARE INSTITUTIONS: AN EVALUATION OF THE COSTS AND CONSEQUENCES
Gonzalez P 1 , Gomez E 2 , Vargas J 3 1 Clínica 196, Instituto Mexicano del Seguro Social, Mexico, Mexico, 2 Centro Médico American British Cowdray, Mexico, DF, Mexico, 3 Econopharma Consulting SA de CV, Mexico, DF, Mexico OBJECTIVES: The aim of this study is to evaluate the effectiveness of RA treatment and the economic impact of the use of methoxypolyethylengycol-epoietin beta (a continuous erythropoietin receptor activator, C.E.R.A.) compared with recombinant human erythropoietin (EPO-alpha). METHODS: A cost-effectiveness analysis was done on the base of a decision tree model that simulates the treatment costs. A systematic review of randomized-comparative clinical trials was performed to determine the effects and risks associated with the degree of hemoglobin/hematocrit (Hgb/ Hct) level variability outside the recommended range. Diagnostic algorithm and guides treatment adaptation were built out of a panel of experts. Resource use and costs data were obtained from the Instituto Mexicano del Seguro Social (IMSS). The costs and effectiveness were discounted annually at 3%. The threshold to define a therapy as cost-effective was fixed at USD$25,020.00 (least than three times Mexican GDP per capita) following the recommendations of WHO's Commission on Macroeconomics and Health. RESULTS: The clinical success rate (patients within 11-12.5 Hbg/dl levels) when using C.E.R.A. vs EPO-alpha showed significant difference (86.79% [95% CI, 84.70%-88.88%] vs 50.48% [95% CI, 47.38%-53.58%] respectively, p 0.0001). The treatment care cost per year for C.E.R.A. was US$2,776.13 (95%CI,US$2,740.9-US$2,811.43) vs US$2,907.88 (95%CI,US$2,883.27-US$2,932.47) for EPO-Beta, (p 0.0001); and the hospitalization cost USD$7,089.74 vs US$11,255.09 for each one. C.E.R.A. therapy reduces the cost of RA treatment in CKD at a 4.53% compared to EPO-alpha therapy and reduced in 37% the hospital stay due to Hgb/Hct levels variation. The Cost-effectiveness plane indicates that C.E.R.A. is a highly cost-effective therapy; with a probability of 0.60 to be cost saving and 0.99 of probability of being cost effective at a USD$4,450 threshold (less than one Mexican PIB per capita). CONCLUSIONS: This results show that the use of C.E.R.A. for the treatment of RA in patients with CKD is cost-effective. (2008) . Rates of disease progression were derived from the PFS Kaplan-Meier curves, mortality rates were obtained from the Scotland-Newcastle Lymphoma Group database and Romanian age-specific mortality tables. The duration of the treatment effect of rituximab was conservatively applied for the period of clinical trial follow-up (90 months) (hazard ratio 0.468). Direct costs included: drug acquisition costs (maximum price from Romanian drugs list 2008), hospitalization costs taken from NSPHHSM and NHIH (2008) and calculated based on the tariff per chemotherapy administration episode, and post-treatment surveillance costs. Costs were discounted by 6.0% p.a. RESULTS: This analysis showed that for each FL treatment where R-CVP is used instead of CVP, the average benefit to the patient would be an additional 0.983 life years gained (LYG), and 0.931 years when quality-adjusted (QALY). Drug acquisition costs were higher with rituximab, however, this was partially offset by lower costs for progression. When R-CVP is compared to CVP alone, the incremental incremental cost per LYG or QALY gained was calculated as a7155 and a7557, respectively. Sensitivity analyses indicated these results were sensitive to the time horizon (longer the time horizon, lower the cost per QALY gained) and that the model was robust. CONCLUSIONS: This study confirms the long-term clinical and economic benefits of adding rituximab to CVP in patients with FL in Romania.
PSY26 ECONOMIC EVALUATION OF THE ADDITION OF RITUXIMAB TO CVP FOR ADVANCED FOLLICULAR LYMPHOMA IN ROMANIA
PSY27
COST-EFFECTIVENESS OF ANTIGUNGAL PROPHYLAXIS WITH POSACONAZOLE VERSUS STANDARD AZOLE THERAPY IN THE PREVENTION OF INVASIVE FUNGAL INFECTIONS AMONG HIGH RISK HAEMATOLOGY PATIENTS IN CZECH REPUBLIC
Suchankova E 1 , Dolezal T 2 , Simonova J 3 1 Charles University, Prague , Czech Republic, 2 Charles University, Praha, Czech Republic, 3 Schering-Plough, Prague, Czech Republic OBJECTIVES: The rising incidence of invasive fungal infections (IFI), especially invasive aspergillosis, compromises therapeutic outcomes in haematologic cancer patients and in transplant recipients.The aim of our analysis was to determine the costeffectiveness of prophylaxis with posaconazole in comparison with standard azole therapy (fluconazole or itraconazole) for risk haematology patients in Czech Republic. METHODS: The decision-tree economic model was developed for patients with acute myelogenous leukemia (AML). The rates of IFI, IFI-related mortality, overall mortality and treatment duration were obtained from randomised controlled trials.The cost of drugs and IFI hospitalisation was obtained from panel of experts. The model estimates total costs, numbers of IFIs, and life-years gained (LYG) per patient in each prophylaxis group. Cost and health effects were discounted at 3%. RESULTS: In comparison with fluconazole/itraconazole prophylaxis, posaconazole prophylaxis was associated with significant reduction in the rates of IFI in AML patients, lower IFI-related deaths and increased life years. Accumulated cost to the Czech health care system per patient receiving the posaconazole regimen was a2770 compared to a2090 for the fluconazole/itraconazole regimen. This results in an incremental cost of a680 per patient. Incremental life-years saved were 0.016 per patient. The corresponding incremental cost effectiveness ratio (ICER) is a42,122 per LYG. Probabilistic sensitivity analysis tested numerous assumptions about the model cost and efficacy parameters and found that the results were robust to most changes. CONCLUSIONS: In addition to the proven efficacy, posaconazole appeared to be cost-effective relative to fluconazole/itraconazole in the prophylaxis of IFIs among patients with AML in the settings of Czech Republic health care.
PSY28 IRON DEFICIENCY IN SWEDEN-TREATMENT OPTIONS, COST-EFFECTIVENESS AND REIMBURSEMENT
Glenngård AH 1 , Borg S 1 , Danielson BG 2 , Persson U 1 1 The Swedish Institute for Health Economics, Lund, Sweden, 2 University Hospital, Uppsala, Sweden BACKGROUND: Iron deficiency and anaemia is common in patients with chronic Iron deficiency and anaemia is common in patients with chronic diseases, e.g. chronic kidney disease (CKD), cancer, inflammatory bowel disease (IBD), and congestive heart failure (CHF) and in connection with large blood losses. One appropriate treatment options is intravenous (IV) iron. In Sweden, the Dental and Pharmaceutical Benefits Agency, TLV, decides if a medicine should be included in the pharmaceutical benefits scheme. TLV makes decisions regarding new products and reviews all pharmaceuticals given reimbursement status before 2002. There are three IV iron products in Sweden; Ferinject (ferric carboxymaltose), approved for reimburse-(ferric carboxymaltose), approved for reimburse-approved for reimbursement in 2008, and two products approved before 2002: Venofer (iron sucrose) and Cosmofer (iron dextran). OBJECTIVES: To present health economic analyses of treatment with intravenous iron compared to relevant treatment options in different patient populations, i.e. EPO and IV iron vs. EPO and oral iron in CKD, EPO and IV iron vs. EPO without iron in cancer, IV Iron vs. no iron in CHF, and IV iron vs. oral iron in post-partum and IBD. METHODS: Incremental costs and effects (ICER) of IV iron therapy are estimated by comparing relevant treatment alternatives in different patient groups. In CKD, cancer and IBD, model simulations are used. In postpartum and CHF, a piggyback approach is used. RESULTS: In patients with cancer and CKD in dialysis, treatment with IV iron and EPO is found to dominate treatment with EPO alone. In IBD patients, intolerant to oral iron, a treatment switch to IV iron generated a cost per QALY of a32,377. The ICER for post-partum and CHF patients given IV iron compared to oral iron is estimated at a22,280 and a13,850, respectively. CONCLUSIONS: The ICER of IV iron treatment compared to relevant alternatives is modest for IBD, post-partum and CHF patients and IV iron is dominant for patients with haematological cancer and CKD.
